Cortexyme, Inc. – NASDAQ:CRTX

Add to watchlist

$1.95

Market closed

Open in 2 days

-21.69%

month

-40.55%

quarter

-98.03%

year

Market Cap	70.45M
Enterprise value	N/A

P/E	-0.65
EV/Sales	N/A
EV/EBITDA	0.05
Price/Sales	N/A
Price/Book	0.55
PEG ratio	0.04
EPS	-4.47

Revenue	N/A
EBITDA	-149.26M
Income	-149.92M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Cortexyme, Inc. (NASDAQ:CRTX): Profit margin
Sep 2021	0	-21.70M
Dec 2021	0	-89.94M
Mar 2022	0	-21.71M
Jun 2022	0	-16.56M

Cortexyme, Inc. (NASDAQ:CRTX): Earnings per share (EPS)
2022-03-01	-0.65	-0.78

Cortexyme, Inc. (NASDAQ:CRTX): Debt to assets
Sep 2021	147416000	14.76M	10.02%
Dec 2021	133228000	14.64M	10.99%
Mar 2022	116130000	9.75M	8.4%
Jun 2022	117863000	6.33M	5.37%

Cortexyme, Inc. (NASDAQ:CRTX): Cash Flow
Jun 2021	-17.56M	5.62M	672K
Sep 2021	-17.34M	766K	4.70M
Dec 2021	-14.41M	20.91M	990K
Mar 2022	-16.09M	13.41M	622K

Cortexyme alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Cortexyme, Inc. (NASDAQ:CRTX): Employee count
Aug 2023	55
Sep 2023	55
Oct 2023	55
Nov 2023	55
Dec 2023	55
Jan 2024	55
Feb 2024	55
Mar 2024	55
Apr 2024	55
May 2024	55
Jun 2024	55
Jul 2024	55

Cortexyme, Inc. (NASDAQ:CRTX): Insider trades (number of shares)
Period	Buy	Sel
Jul 2021	0	116522
Aug 2021	0	38000
Oct 2021	0	5963
Nov 2021	763	0
Jun 2022	0	10800

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	6 Jun 2022	MCDOWELL CARYN GORDON officer: Chief Le..	Common Stock	10,800	$2.86	$30,920
Option	18 Nov 2021	LYNCH CASEY director, officer..	Stock Option (Right to Buy)	60,000	$0.46	$27,600
Option	18 Nov 2021	LYNCH CASEY director, officer..	Common Stock	60,000	$0.46	$27,600
Option	16 Nov 2021	LOWE CHRISTOPHER P. officer: COO & Chief Financial Officer officer: COO & Chief Financial ..	Stock Option (right to buy)	30,000	$2.23	$66,900
Option	16 Nov 2021	LOWE CHRISTOPHER P. officer: COO & Chief Financial Officer officer: COO & Chief Financial ..	Common Stock	30,000	$2.23	$66,900
Purchase	12 Nov 2021	DOMINY STEPHEN S. director, officer: Chief Scientific Offi.. director, officer: Chief Scient..	Common Stock	763	$14.4	$10,987
Option	8 Oct 2021	MCLOUGHLIN MARGARET director director	Stock Option (right to buy)	1,000	$17	$17,000
Sale	8 Oct 2021	MCLOUGHLIN MARGARET director director	Common Stock	1,000	$88.93	$88,930
Option	8 Oct 2021	MCLOUGHLIN MARGARET director director	Common Stock	1,000	$17	$17,000
Option	5 Oct 2021	LOWE CHRISTOPHER P. officer: COO & Chief Financial Officer officer: COO & Chief Financial ..	Stock Option (Right to Buy)	4,963	$54.85	$272,221

Status	Patent	Filling date	Issue date
Application	Application ARGININE GINGIPAIN INHIBITORS Filling date: 20 Mar 2020 Issue date: 30 Jun 2022	20 Mar 2020	30 Jun 2022
Grant	Grant Utility: Inhibitors of lysine gingipain Filling date: 4 May 2020 Issue date: 17 May 2022	4 May 2020	17 May 2022
Grant	Grant Utility: Ketone inhibitors of lysine gingipain Filling date: 11 Jun 2020 Issue date: 10 May 2022	11 Jun 2020	10 May 2022
Application	Application METHODS FOR DETECTION OF MICROBIAL NUCLEIC ACIDS IN BODY FLUIDS Filling date: 27 Sep 2019 Issue date: 18 Nov 2021	27 Sep 2019	18 Nov 2021
Application	Application AMINOPYRIDINE COMPOUNDS AND METHODS FOR THE PREPARATION AND USE THEREOF Filling date: 8 Jul 2021 Issue date: 4 Nov 2021	8 Jul 2021	4 Nov 2021
Grant	Grant Utility: Aminopyridine compounds and methods for the preparation and use thereof Filling date: 8 Nov 2019 Issue date: 13 Jul 2021	8 Nov 2019	13 Jul 2021
Application	Application KETONE INHIBITORS OF LYSINE GINGIPAIN Filling date: 11 Jun 2020 Issue date: 25 Feb 2021	11 Jun 2020	25 Feb 2021
Grant	Grant Utility: Inhibitors of arginine gingipain Filling date: 9 May 2018 Issue date: 2 Feb 2021	9 May 2018	2 Feb 2021
Application	Application INHIBITORS OF LYSINE GINGIPAIN Filling date: 4 May 2020 Issue date: 21 Jan 2021	4 May 2020	21 Jan 2021
Grant	Grant Utility: Ketone inhibitors of lysine gingipain Filling date: 14 Mar 2019 Issue date: 4 Aug 2020	14 Mar 2019	4 Aug 2020

Cortexyme
Earnings Call Transcripts

Quarter	Transcript
Q3 2013 7 Nov 2013	Q3 2013 Earnings Call Transcript
Q2 2013 6 Aug 2013	Q2 2013 Earnings Call Transcript
Q1 2013 9 May 2013	Q1 2013 Earnings Call Transcript
Q4 2012 14 Mar 2013	Q4 2012 Earnings Call Transcript

CRTX earnings call transcripts

Cortexyme
Executives

Insider	Age	Compensation
Ms. Casey C. Lynch (1974) Co-Founder, Chairman, Pres & Chief Executive Officer	51	$787,500
Dr. Michael J. Detke M.D., Ph.D. (1967) Chief Medical Officer	58	$574,000
Dr. Leslie J. Holsinger Ph.D. (1965) Executive Vice President of R&D	60	$567,000
Mr. Christopher P. Lowe M.B.A. (1971) Chief Operating Officer, Chief Financial Officer & Treasurer	54	$546,000
Ms. Caryn Gordon McDowell (1970) Chief Legal & Admin. Officer and Corporation Sec.	55	$513,160

Cortexyme
Latest News

Tuesday, 15 March 2022
12:56	Short-Squeeze Stocks: Top 10 Stocks With High Short Interest Today	InvestorPlace
Tuesday, 8 March 2022
11:27	Cortexyme Posts Safety Data From SAD Portion Of COR588 Trial In P.Gingivalis	Benzinga
Monday, 28 February 2022
21:15	Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment	Seeking Alpha
Friday, 18 February 2022
11:39	Here's Why Cortexyme, Inc. (CRTX) is Poised for a Turnaround After Losing 52% in 4 Weeks	Zacks Investment Research
Wednesday, 2 February 2022
11:33	After Plunging 47.5% in 4 Weeks, Here's Why the Trend Might Reverse for Cortexyme, Inc. (CRTX)	Zacks Investment Research
Tuesday, 1 February 2022
11:36	5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI	InvestorPlace
Wednesday, 26 January 2022
15:21	Cortexyme Stock Sinks After FDA Puts Application on Hold	Schaeffers Research
09:13	Cortexyme Stock Plunges On FDA Hold On Atuzaginstat's IND	Benzinga
Wednesday, 12 January 2022
10:00	Why Cortexyme Stock Imploded in 2021	The Motley Fool
Friday, 7 January 2022
15:21	3 Most-Shorted Stocks at 52-Week Lows to Buy	InvestorPlace
Friday, 17 December 2021
13:50	The 10 Most Shorted Stocks Right Now for Friday, Dec. 17	InvestorPlace
Wednesday, 15 December 2021
15:46	Cortexyme: Drug Candidate COR588 May Offer Some Hope To Investors	Seeking Alpha
Monday, 6 December 2021
10:00	5 Short Squeeze Candidates To Watch: Pioneer Power, NuZee Remain At The Top, Grab Rejoins The Leaderboard	Benzinga
Wednesday, 1 December 2021
10:44	Is the Options Market Predicting a Spike in Cortexyme (CRTX) Stock?	Zacks Investment Research
Wednesday, 17 November 2021
00:06	Cortexyme: A Challenging Path Forward	Seeking Alpha
Thursday, 11 November 2021
12:54	Why Are Cortexyme Shares Falling Today?	Benzinga
Friday, 5 November 2021
05:53	Alzheimer's - Cassava Sciences, Cortexyme Or Anavex: Who Will Come On Top?	Seeking Alpha
Wednesday, 3 November 2021
12:19	This Is What Whales Are Betting On Cortexyme	Benzinga
Thursday, 28 October 2021
10:00	Down 76%: Is Cortexyme Stock a Bargain?	The Motley Fool
05:25	Cortexyme's Alzheimer's Drug Fails -- 2 Lessons for Investors	The Motley Fool
Wednesday, 27 October 2021
14:56	CRTX Stock: What to Know as Cortexyme Plummets 75%	InvestorPlace
13:55	Why Cortexyme Shares Are Falling	Benzinga
12:43	Here's Why Cortexyme Is Imploding on Wednesday	The Motley Fool
10:20	Cortexyme's stock tumbles on failed clinical trial for Alzheimer's drug	Market Watch
Tuesday, 26 October 2021
17:55	Why Cortexyme Shares Are Plunging 70% After Hours	Benzinga
Saturday, 16 October 2021
07:30	SA Interview: Investing In The Pharmaceutical Industry With Small Pharma Analyst	Seeking Alpha
Monday, 11 October 2021
08:30	Cortexyme And The Gingipain Hypothesis Of Alzheimer's Disease	Seeking Alpha
Sunday, 12 September 2021
06:33	Cortexyme: Alzheimer's Readout In November A Binary Event	Seeking Alpha
Monday, 16 August 2021
16:09	Cortexyme: Shifting The Odds In Your Favor So Your Best Case Outcome Is Three Times Higher Than Your Worst Case	Benzinga

Ideas & Opinions

Seeking Alpha 1 Mar 2022

Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment
Seeking Alpha 15 Dec 2021

Cortexyme: Drug Candidate COR588 May Offer Some Hope To Investors
Seeking Alpha 17 Nov 2021

Cortexyme: A Challenging Path Forward
Seeking Alpha 5 Nov 2021

Alzheimer's - Cassava, Cortexyme Or Anavex: Who Will Come On Top?
Seeking Alpha 16 Oct 2021

SA Interview: Investing In The Pharmaceutical Industry With Small Pharma Analyst
Seeking Alpha 11 Oct 2021

Cortexyme And The Gingipain Hypothesis Of Alzheimer's Disease
Seeking Alpha 12 Sep 2021

Cortexyme: Alzheimer's Readout In November A Binary Event
Seeking Alpha 7 Jul 2021

Biogen Controversy And The Spillover Effect: Actionable Insights

Frequently Asked Questions (FAQ)

What's the price of Cortexyme stock today?

One share of Cortexyme stock can currently be purchased for approximately $1.95.
When is Cortexyme's next earnings date?

Unfortunately, Cortexyme's (CRTX) next earnings date is currently unknown.
Does Cortexyme pay dividends?

No, Cortexyme does not pay dividends.
How much money does Cortexyme make?

Cortexyme has a market capitalization of 70.45M. Cortexyme made a loss 89.95M US dollars in net income (profit) last year or -$0.78 on an earnings per share basis.
What is Cortexyme's stock symbol?

Cortexyme, Inc. is traded on the NASDAQ under the ticker symbol "CRTX".
What is Cortexyme's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Cortexyme?

Shares of Cortexyme can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Cortexyme's key executives?
Cortexyme's management team includes the following people:
- Ms. Casey C. Lynch Co-Founder, Chairman, Pres & Chief Executive Officer(age: 51, pay: $787,500)
- Dr. Michael J. Detke M.D., Ph.D. Chief Medical Officer(age: 58, pay: $574,000)
- Dr. Leslie J. Holsinger Ph.D. Executive Vice President of R&D(age: 60, pay: $567,000)
- Mr. Christopher P. Lowe M.B.A. Chief Operating Officer, Chief Financial Officer & Treasurer(age: 54, pay: $546,000)
- Ms. Caryn Gordon McDowell Chief Legal & Admin. Officer and Corporation Sec.(age: 55, pay: $513,160)
Is Cortexyme founder-led company?

Yes, Cortexyme is a company led by its founder Ms. Casey C. Lynch.
How many employees does Cortexyme have?

As Jul 2024, Cortexyme employs 55 workers.
When Cortexyme went public?

Cortexyme, Inc. is publicly traded company for more then 6 years since IPO on 9 May 2019.
What is Cortexyme's official website?

The official website for Cortexyme is cortexyme.com.
Where are Cortexyme's headquarters?

Cortexyme is headquartered at 269 E Grand Ave, South San Francisco, CALIFORNIA.
How can i contact Cortexyme?

Cortexyme's mailing address is 269 E Grand Ave, South San Francisco, CALIFORNIA and company can be reached via phone at +1 415 910 5717.

Cortexyme, Inc.

cortexyme.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

+1 415 910 5717

269 E Grand Ave
South San Francisco, CALIFORNIA 94080

CIK: 0001662774
ISIN: US22053A1079
CUSIP: 22053A107